Annual report pursuant to Section 13 and 15(d)

Note 19 - Agreements (Details Textual)

v3.19.1
Note 19 - Agreements (Details Textual)
 1 Months Ended 12 Months Ended
Mar. 03, 2017
$ / shares
shares
Mar. 31, 2017
$ / shares
shares
Jul. 31, 2014
USD ($)
Sep. 30, 2013
Dec. 31, 2011
USD ($)
Nov. 30, 2009
Jan. 31, 2002
USD ($)
Dec. 31, 2018
USD ($)
$ / shares
Dec. 31, 2017
USD ($)
$ / shares
shares
Common Stock, Par or Stated Value Per Share | $ / shares $ 0.001             $ 0.001 $ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares [1]               $ 1.15  
Research and Development Expense, Total               $ 4,221,881 $ 4,513,842
Maximum [Member]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares               $ 2.50  
Series NN Warrants [Member]                  
Class of Warrant or Right, Term   5 years              
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares   $ 1.50           $ 1.50  
Series NN Warrants [Member] | UCSD [Member]                  
Class of Warrant or Right, Term 5 years                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares 1,000,000 1,000,000             1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1.50                
Reliable Supply Agreement [Member]                  
Long-term Contract for Supplies, Initial Term           10 years      
Long-term Contract for Supplies, Option to Extend, Term           3 years      
Long-term Contract for Supplies, Resolution Term           60 days      
Purchases Under Manufacture and Supply Agreement               $ 0 $ 0
OsoBio Supply Agreement [Member]                  
Long-term Contract for Supplies, Resolution Term       60 days          
Purchases Under Manufacturing Agreement               0 250,000
Gipharma Supply Agreement [Member]                  
Long-term Contract for Supplies, Initial Term       3 years          
Long-term Contract for Supplies, Renewal Term       1 year          
Purchases Under Service and Supply Master Agreement               0 14,000
Tc99m Tilmanocept License Agreement [Member]                  
License Issue Fee             $ 25,000    
License Maintenance Fee             25,000    
Minimum Annual Royalty             $ 25,000    
Expanded Tc99m Tilmanocept License Agreement [Member] | Outside the Territory [Member] | Cost of Sales [Member] | License [Member]                  
Cost of Goods and Services Sold, Total               1,000 4,000
Amended and Restated Tilmanocept License Agreement [Member]                  
Research and Development Expense, Total               35,000 34,000
Tilmanocept License Agreement [Member]                  
License Issue Fee     $ 25,000            
License Maintenance Fee     25,000            
Minimum Annual Royalty     $ 25,000            
Research and Development Expense, Total               250,000 253,000
Astra Zeneca Agreement [Member]                  
Milestone Payments, Maximum, Cash, Clinical Development and Regulatory Filing Milestones         $ 6,500,000        
Milestone Payments, Maximum, Cash, Due Following Receipt of Regulatory Approvals and Initiation of Commercial Sales         11,000,000        
Astra Zeneca Agreement [Member] | License [Member]                  
Cost of Goods and Services Sold, Total         $ 5,000,000        
Alseres Pharmaceuticals Agreement [Member]                  
Research and Development Expense, Total               $ 0 $ 70,000
Ratio of Entitled Salary               4.25  
Employment Agreement [Member] | Maximum [Member]                  
Loss Contingency, Estimate of Possible Loss               $ 2,000,000  
[1] Weighted average exercise price.